Takeda benefits from one-offs but Actos already weighing heavily
This article was originally published in Scrip
Executive Summary
The main take-aways from Takeda's first quarter figures were the precipitous plunges in both group operating profit and global sales of top product Actos (pioglitazone) ahead of the oral antidiabetic's loss of US exclusivity next month.